Other targeted agents evaluated in specific oncogenically addicted patient populations in the early trial setting, such as vemurafenib [3] or dabrafenib [4] in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutant melanoma, or crizotinib in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocated non-small cell lung cancer [5], have demonstrated dramatic antitumor activity. This evidence concerns the gene BRAF and lung carcinoma.